News · 26 weeks58-15%
2025-10-262026-04-19
Mix3290d
- Insider14(44%)
- Other8(25%)
- SEC Filings7(22%)
- Leadership2(6%)
- Earnings1(3%)
Latest news
25 items- PRFemasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026ATLANTA, April 22, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the commercial launch of FemaSeed Complete, a comprehensive fertility solution that enables OB/GYNs to perform first-line insemination entirely within their own practices. An estimated 10 million women in the United States experience infertility, yet fewer than half access care, and only a very small percentage ultimately undergo IVF. At the same time, U.S. fertility rates declined again in 2025 to a record low, underscoring the growing need for ear
- PRFemasys Drives International Growth with Israeli Market Entry for Fertility Portfolio-- Partnership with AMI Technologies Positions FemaSeed® as a First-Line Infertility Treatment in Israel, Expanding Market Access to Innovative Fertility Solutions -- ATLANTA, April 16, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today a strategic partnership with AMI Technologies to introduce and commercialize its fertility portfolio in Israel. This collaboration marks an important step in the Company's global expansion strategy and is expected to broaden international market access and drive adoption of innovative
- SECSEC Form DEF 14A filed by Femasys Inc.DEF 14A - FEMASYS INC (0001339005) (Filer)
- INSIDERSEC Form 4 filed by Canning John Charles4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 3 filed by new insider Canning John Charles3 - FEMASYS INC (0001339005) (Issuer)
- SECFemasys Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- PRFemasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial GrowthATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption. Prior to joining
- SECSEC Form S-8 filed by Femasys Inc.S-8 - FEMASYS INC (0001339005) (Filer)
- SECSEC Form 10-K filed by Femasys Inc.10-K - FEMASYS INC (0001339005) (Filer)
- SECFemasys Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- PRFemasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate UpdateATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provides a corporate update. Corporate Highlights from 4Q 2025 to date Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, advancing toward U.S. approval.Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.FemBloc permanent birth control system achieved certification under the Medical Device Single Au
- INSIDERSEC Form 4 filed by Lee-Sepsick Kathy4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Elefant Dov4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Larsen Charles4 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Eichenbaum Kenneth D.4 - FEMASYS INC (0001339005) (Issuer)
- SECSEC Form PRE 14A filed by Femasys Inc.PRE 14A - FEMASYS INC (0001339005) (Filer)
- INSIDERSEC Form 3 filed by new insider Eichenbaum Kenneth D.3 - FEMASYS INC (0001339005) (Issuer)
- INSIDERSEC Form 4 filed by Eichenbaum Kenneth D.4 - FEMASYS INC (0001339005) (Issuer)
- SECFemasys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits8-K - FEMASYS INC (0001339005) (Filer)
- INSIDERSEC Form 4 filed by Pharmacyte Biotech, Inc.4 - FEMASYS INC (0001339005) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Femasys Inc.SCHEDULE 13G - FEMASYS INC (0001339005) (Subject)
- INSIDERSEC Form 4 filed by Silverman Joshua4 - FEMASYS INC (0001339005) (Issuer)
- PRFemasys Appoints Dr. Kenneth D. Eichenbaum to Board of DirectorsATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel
- PRFemasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the initiation of patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc. This milestone follows U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to advance the study based on positive clinical data generated in its
- PRFemasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has granted to two new non-executive employees who began their employment with Femasys in February 2026 options to purchase 185,000 shares of Femasys common stock. These inducement grants were granted at an exercise price per share of $0.50 and $0.57, equal to the closing price of Femasys common stock on the date of employment as reported by Nasdaq. This grant was approved by the Compensation Committee of Femasys' Board of Directors and made as an inducement